• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Telecon with Fresenius Kabi - 11/30/2007

Telecon with Fresenius Kabi

RE: BN070012

Meeting called by: Franklin. Stephenson/ RPM
Type of meeting: Telecon
FDA Participants: Franklin Stephenson, Dr. Lawrence Landow
Baxter Participants: Mr. Coln


Conversation Record:

  • We contacted Mr. Coln and told him of the new Pediatric Research Equity Act (PREA) requirement that pediatric studies must be done in children. Dr. Landow explained that there were 3 categories in children: new born to 2 years, 2 years to 12 years and 12 years to 16 years.



  • Mr. Coln stated that Fresenius Kabi had provided a pediatric statement in Module 2 Vol 4, 3rd tab.



  • Dr. Landow noted that Fresenius Kabi had only done study in new born to 2 year old and needed to provide justification as to why a waiver should be granted for those age groups.



  • Mr. Coln told us that we would bring the issue to F. Kabi and would get back to us ASAP.


Franklin T. Stephenson
Regulatory Project Manager